Clinical trials: GLP - 1
Obesity
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
- Trial name
- NCT04186026
- Testing
- Saline + saline, Neurotensin + saline, GLP-1 + saline
- Where
- 2 sites in Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes Mellitus, Coronary Artery Disease
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010683
- Testing
- Liraglutide, Metformin
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Athens
Vagotomy, Truncal
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake.
- Trial name
- NCT01176890
- Testing
- GLP-1, Saline
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Liver Transplantation
Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion
The aim of the study is to investigate the significance of intact nerve supply to the liver for the glucagon-like peptide-1 (GLP-1) induced insulin secretion.
- Trial name
- NCT01176708
- Testing
- dipeptidyl peptidase 4 (DPP4) inhibitor, oral glucose, intravenous glucose
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes Mellitus, Steroids
Incretin Physiology Associated With Steroid Hormone Treatment
The purpose of this study is to evaluate whether the reduced incretin effect and the paradoxical glucagon responses during oral glucose ingestion and isoglycaemic iv glucose infusion observed in patients with type 2 diabetes are…
- Trial name
- NCT00713440
- Testing
- Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 2 Diabetes Mellitus
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
Incretinbased treatment of patients with type 2 diabetes mellitus (T2DM) has increasing interest. The incretin glucagon-like peptide-1 (GLP-1) stimulates beta-cells to increased secretion and production of insulin.
- Trial name
- NCT00655603
- Testing
- Infusion of native hormones from the pancreas and gut (GLP-1)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Incretin Effect
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, respectively.
- Trial name
- H-21044858 (NCT06194955)
- Testing
- GIP(1-42), GLP-1, GLP-2
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy Adult Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects.
- Trial name
- NCT06562088
- Testing
- HDM1002 and rifampicin, HDM1002 and itraconazole
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pregnant Individuals, Obesity & Overweight
Gestational Response, Outcomes, and Weight After GLP-1 Use
The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes.
- Conditions
- Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain
- Trial name
- GROW (NCT07743567)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Healthy
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants.
- Trial name
- NCT06370728
- Testing
- Orforglipron, Carbamazepine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Appetite and General Nutritional Disorders, Hormone Replacement
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY
The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gut.
- Trial name
- NCT01088841
- Testing
- lactisole
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
GLP - 1, Bowel Preparation for Colonoscopy
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies.
- Trial name
- NCT07127354
- Testing
- Continue GLP/GIP
- Where
- 3 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Coronary Artery Disease, Diabetes Mellitus Type 2
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
The overall goal of this proposal is to determine the effects of acute hyperglycemia and its modulation by Glucagon-like Peptide-1 (GLP-1) on myocardial perfusion in type 2 diabetes (DM).
- Trial name
- GLP-1 (NCT01021865)
- Testing
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy
A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects
The purpose of the study is to standardize a meal test to facilitate future studies of the postprandial glucagons-like peptide 1 (GLP-1) response in Chinese subjects.
- Trial name
- IC-1-V1 (NCT00884091)
- Where
- Taiwan
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Headache, Migraine
Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans
Studying glucagon-like peptide-1 (GLP-1) induced vasodilatory effects on extra - and intracerebral arteries and headache in healthy volunteers and migraine patients without aura.
- Trial name
- NCT04232605
- Testing
- GLP-1 peptide
- Where
- Denmark
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Danish Headache Center
Healthy
DPP4 Inhibition & Beta Cell Function
This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting…
- Trial name
- NCT02683187
- Testing
- Active Comparator: Sitagliptin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Type 2 Diabetes
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult…
- Trial name
- NCT06634927
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Adult Subject
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
In this study, a single dose of [14C] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize…
- Trial name
- NCT06576401
- Testing
- [14C] HDM1002
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Post-bariatric Surgery
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the…
- Trial name
- GLP-1 (NCT01803451)
- Testing
- exendin-(9-39), exendin -(9-39)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio